Dendritic cells (DCs) have a critical role in tumor-specific immune response stimulation which is of great interest for immunological- based therapy research, such as anti-tumor cell vaccines with autologous DCs. For this purpose it is important to have a greater understanding on the number and function of DCs and on the optimal conditions for their collection and administration. Most studies reveal difficulties in the identification of DCs subpopulations.
Dendritic Cells Exclusion Kit is a combination of monoclonal antibodies directed against T-cells (CD3+), B-cells (CD19+), NKcells (CD56+) and monocytes (CD14+), all of them conjugated with FITC. Peripheral blood dendritic cells can be distinguished from other leucocytes by their characteristic lack of staining with this combination and an intermediate pattern of FSC/SSC between lymphocytes and monocytes.
CD3 + CD14 + CD19 + CD56
The combination of Dendritic Cells Exclusion Kit with other antibodies such as anti-human HLA-DR allows a clear identification of total dendritic cell population. Additionally, the use of this kit combined with anti-human CD33, CD123 and/or CD16 antibodies allows the identification of different dendritic cell subpopulations.